BMS Keeping ConvaTec, Cutting Zimmer: Matching Howmedica May Be Hard

Bristol-Myers Squibb's exit from non-pharmaceutical businesses will not include the divestiture of ConvaTec. BMS is retaining the wound management business with the goal of reversing the division's recent sluggish sales results.